

Original Article

P Wave Duration And Dispersion In Patients With Hyperthyroidism And The Short-term Effects Of Antithyroid Treatment

Unal Guntekin, MD¹, Yilmaz Gunes, MD¹, Hakki Simsek, MD¹, Mustafa Tuncer, MD¹, Sevket Arslan MD²

¹YuzuncuYil University, Faculty of Medicine, Cardiology Department, Van, Turkey.

²Yuzuncu Yil University, Faculty of Medicine, Internal Medicine Department, Van, Turkey.

Address for correspondence: Hakki Simsek, Yuzuncu Yil University, Faculty of Medicine, Cardiology Department, Van, Turkey. E-mail: dr.hsimsek/at/hotmail.com

Abstract

Background: Prolonged P wave duration and P wave dispersion (PWD) have been associated with an increased risk for atrial fibrillation (AF). Hyperthyroidism is a frequent cause of atrial fibrillation (AF).

Methods: Forty-two patients with newly diagnosed overt hyperthyroidism and 20 healthy people were enrolled in the study. Transthoracic echocardiography, 12 lead surface ECG and thyroid hormone levels were studied at the time of enrollment and after achievement of euthyroid state with propylthiouracil treatment.

Results: Maximum P wave duration (Pmax) (97.4 ± 14.6 vs. 84.2 ± 9.5 msec, $p < 0.001$), PWD (42.9 ± 10.7 vs. 31.0 ± 6.2 msec, $p < 0.001$), deceleration (DT) (190.7 ± 22.6 vs. 177.0 ± 10.2 msec, $p = 0.013$) and isovolumetric relaxation times (IVRT) (90.9 ± 11.2 vs. 79.6 ± 10.5 msec, $p < 0.001$) were significantly higher in hyperthyroid patients compared to control group. Pmax and PWD were significantly correlated with the presence of hyperthyroidism. Pmax (97.4 ± 14.6 to 84.3 ± 8.6 msec, $p < 0.001$) Pmin (54.1 ± 8.6 to 48.1 ± 8.5 msec, $p = 0.002$), PWD (42.9 ± 10.7 to 35.9 ± 8.1 msec, $p = 0.002$) and DT (190.7 ± 22.6 to 185.5 ± 18.3 , $p = 0.036$) were significantly decreased after achievement of euthyroid state in patients with hyperthyroidism. Diastolic dysfunction was seen in 5 patients at hyperthyroid state but only in one patient at euthyroid state.

Conclusions: Hyperthyroidism is associated with prolonged P wave duration and dispersion. Achievement of euthyroid state with propylthiouracil treatment results in shortening of P wave variables. Diastolic function may have a partial effect for the increased Pmax and PWD. Shortening of Pmax and PWD may be a marker for the prevention of AF with the anti-thyroid treatment.

Key words: Hyperthyroidism; P wave dispersion; atrial fibrillation; propylthiouracil

Introduction

Hyperthyroidism has profound effects on the heart, including increased heart rate, slightly enhanced systolic function, left ventricular (LV) hypertrophy, and diastolic dysfunction [1-9]. Atrial fibrillation (AF) is the most common cardiac dysrhythmia in the adult population. Hyperthyroidism is a major cause of paroxysmal and latent atrial fibrillation (AF) [10-12] and AF, after the sinus tachycardia, is the second common dysrhythmia in patients with hyperthyroidism. Approximately in 10 – 15 % of hyperthyroid patients AF develop [13].

P-wave duration and P-wave dispersion (PWD) are electrocardiographic (ECG) signs of prolongation of intraatrial and interatrial conduction time and inhomogeneous propagation of sinus impulses that are well known electrophysiological characteristics of the atrium prone to fibrillate [14-17].

In the present study, we aimed to evaluate P wave variables and LV diastolic function in hyperthyroid patients and to search the effects of shortterm propyl thio uracil (PTU) treatment.

Materials and Methods

Forty two consecutive hyperthyroid patients followed at out patient clinic of the endocrinology and metabolism department of the hospital and 20 healthy euthyroid healthy voluntary people were evaluated with 12-lead ECG and transthoracic echocardiography. Patients with systemic hypertension, diabetes mellitus, history of structural or ischemic heart disease, chronic obstructive pulmonary disease or any associated systemic disease and patients using systemic drugs, like steroids, antiarrhythmics or antipsychotics, were excluded. The study was approved by the Yuzuncu Yil University, Faculty of Medicine Ethics Committee in accordance with the Declaration of Helsinki. All participants were informed about the study and their consents were obtained.

In the patient group ECG and echocardiographic examinations were performed before treatment and after achievement of euthyroid state with PTU treatment.

Assessment of thyroid status

The evaluation of thyroid morphology and function was performed by clinical examination, assessment of serum free thyroid hormone T3 and T4 (FT3 and FT4) and thyroid stimulating hormone (TSH) levels, and ultrasound examination of the thyroid gland. A total of 5 ml of venous blood samples were drawn and then centrifuged at 2000 rpm for 10 min in a refrigerated centrifuge to separate serum. Serum FT3, FT4, TSH, levels were measured using the commercial Immulite kits, which are solid-phase, two-site chemiluminescent immunometric assay in Immulite autoanalyser (IMMULITE, DPC, USA). The normal reference intervals were 0.80 – 1.80 ng / dl, 1.8 – 4.2 pg/ ml and 0.40 – 4.0 mIU / ml for FT4, FT3 and TSH respectively.

Echocardiographic examination

The echocardiographic examination was performed at rest, with the patient at left lateral decubitus position, using a commercially available echocardiographic device (Vivid 3, General Electric) with a 3 MHz transducer, by two experienced echocardiographers who were blinded to the clinical data. Using M-mode echocardiography, long-axis measurements were obtained at the level distal to the mitral valve leaflets according to current recommendations of the American

Society of Echocardiography [18]. The pulsed Doppler sampling volume was placed between the tips of the mitral valve leaflets to obtain maximum filling velocities. Early diastolic flow (E), atrial contraction signal (A), E/A ratio and E deceleration time (DT) were measured. Isovolumetric relaxation time (IVRT) was determined as the interval between the end of the aortic outflow and the start of the mitral inflow signal.

Tissue Doppler imaging (TDI) was acquired to assess diastolic function. The pulsed wave spectral mode was used for TDI. Filters and baselines were corrected when the velocity ranged between -20 and 20 cm/s. From the apical 4-chamber view, a 5-mm sample volume was placed at the lateral corner of the mitral annulus. Early (Em) and late (Am) diastolic velocities were obtained. All values were measured on three separate beats and then averaged for all parameters.

Impaired left ventricular relaxation was defined as having an E/A ratio of <1 (<0.5 for >50 years), DT >200 msec and IVRT >100 msec (>105 msec for >50 years), all together and/or E/Em ratio of >10 and Ea <10 cm/sec in the presence of a preserved ejection fraction [19].

Electrocardiographic assessment

Twelve-lead ECGs were obtained at rest, with 20 mm/mV amplitude and 50 mm/sec rate with standard lead positions. ECGs were manually measured by the use of a magnifying glass by two blinded cardiologists having no information about the patients. The beginning of the P wave was defined as the point where the initial deflection of the P wave crossed the isoelectric line, and the end of the P wave was defined as the point where the final deflection of the P wave crossed the isoelectric line. The difference between maximum and minimum P wave duration was defined as PWD (**Figure 1**).




Figure 1: Two complexes extracted from 12-lead surface ECG of a patient with iron deficiency anemia. In this case, maximum P-wave duration was observed from lead aVF and the minimum P-wave duration from lead aVR. PWD was defined as the difference between the maximum and minimum P-wave durations.

Intra-observer and inter-observer coefficients of variation for echocardiographic parameters and P wave variables were found to be less than 5% and nonsignificant.

Statistical analysis

Data were presented as mean \pm standard deviation (SD). Using an SPSS package 10.0 (SPSS

Inc., Chicago, Illionis, USA) the changes of parameters after treatment were compared with paired t-tests. Differences in mean values between groups were assessed using the Student t test and with Mann-Whitney's U-test for variables without normal distribution. Pearson correlation analysis was used to assess the correlation between variables. A two-tailed p value < 0.05 was considered significant.

Results

Maximum P wave duration, PWD, DT and IVRT were significantly higher in hyperthyroid patients compared to control group (**Table 1**). PWD was significantly correlated with presence of hyperthyroidism ($r=0.501$, $p<0.001$), IVRT ($r=0.390$, $p=0.002$), E/A ($r=-0.350$, $p=0.005$), DT ($r=0.327$, $p=0.010$), presence of diastolic dysfunction ($r=0.298$, $p=0.019$) and age ($r=0.255$, $p=0.045$). Pmax was also significantly correlated with hyperthyroidism ($r=0.404$, $p=0.001$), age ($r=0.270$, $p=0.034$), E/A ($r=-0.313$, $p=0.013$), diastolic dysfunction ($r=0.268$, $p=0.035$), IVRT ($r=0.265$, $p=0.038$) and DT ($r=0.259$, $p=0.042$).

Table 1: Comparison of baseline characteristics of hyperthyroid patients with control group

Characteristics	Patient Group (n=42)	Control Group (n=20)	P value
Age(years)	38.69±10.50	37.15±10.49	0.591
Sex (female),n	32	14	0.757
BMI, kg/m ²	25.31±5.34	25.12±4.59	0.102
Heart rate (bpm)	90.48±19.60	79.20±13.74	0.024
Systolic BP (mmHg)	122.38±19.29	121.00±11.99	0.770
Diastolic BP (mmHg)	80.95±11.44	76.50±6.71	0.113
LA diameter	3.31±0.33	3.22±0.27	0.273
LVEF, (%)	62.67±3.94	63.35±2.30	0.476
DT (msec)	190.7±22.6	177.0±10.2	0.013
IVRT (msec)	90.9±11.2	79.6±10.5	<0.001
E/A	1.2±0.3	1.3±0.2	0.351
Diastolic dysfunction, n	5	0	0.165
P min (msec)	54.0±8.6	53.2±10.7	0.096
Pmax (msec)	97.4±14.6	84.2±9.5	<0.001
PWD (msec)	42.9±10.7	31.0±6.2	<0.001

Euthyroid state was achieved during a $2,5\pm 0,8$ months. Pmax, Pmin, PWD and DT were significantly decreased after achievement of euthyroid state in patients with hyperthyroidism (Table 2, Figure 2). The slight decrease in IVRT was not significant. Diastolic dysfunction was observed in 5 patients at hyperthyroid state but only in one patient at euthyroid state.

Table 2: Comparison of pre- and post-treatment some echocardiographic values, thyroid hormones and P wave variables

	Hyperthyroid state (n=42)	Euthyroid state (n=42)	P value
DT	190.7 \pm 22,6	185.5 \pm 18.3	0.036
IVRT	90.9 \pm 11.2	88.8 \pm 9.7	0.138
E/A	1.17 \pm 0.21	1.25 \pm 0.27	0.002
PAB (mmHg)	25.2 \pm 12.5	23.8 \pm 11.2	0.083
Heart rate (bpm)	90.5 \pm 19.6	74.1 \pm 13.8	<0.001
TSH	0.02 \pm 0.03	0.55 \pm 1.27	0.011
FT3	7.05 \pm 3.57	4.14 \pm 1.90	<0.001
FT4	3.81 \pm 2.57	1.31 \pm 0.35	<0.001
Pmin (msec)	54.1 \pm 8.6	48.1 \pm 8.5	0.002
Pmax (msec)	97.4 \pm 14.6	84.3 \pm 8.6	<0.001
PWD (msec)	42.9 \pm 10.7	35.9 \pm 8.1	0.002




Figure 2: Error bar of pre- and post-treatment P wave dispersion (PWD), SE: Standard error

Discussion

In this study we found that P maximum and PWD values were increased in hyperthyroidism and treatment with PTU results in improvement in Pmax, PWD and LV diastolic function parameters.

The correlation between the presence of intraatrial conduction abnormalities and the induction of paroxysmal AF has been well documented [15,20]. P-wave dispersion has been advocated as a novel measurement of the heterogeneity of atrial depolarizations [21]. The increase in dispersion of atrial refractoriness may favor a re-entry mechanism leading to AF because fragmentation of the depolarizing wave front may occur when it faces adjoining atrium with nonuniform refractoriness [21,22]. Accordingly, prolonged P-wave duration and increased PWD have been reported to carry an increased risk for AF [14,15].

Frequency of AF is increased in hyperthyroidism [13]. The cardiovascular effects of hyperthyroidism result from the increased metabolic demands of the body tissues and from the direct chronotropic and inotropic effects of excess thyroid hormone on the heart. Thyroid hormone alters the action potential duration and the speed of repolarization of atrial and ventricular myocytes [23,24]. Thyroid hormone administration shortens action potential duration and decreases the refractoriness of cardiomyocytes facilitating the maintenance of multiple reentrant circuits in hearts [25].

Increase in Pmax and PWD values have been reported in hyperthyroidism [26]. Direct effects of thyroid hormones on ionic channels and action potential [23-25] and increased sympathetic activity [27,28] may be responsible for this finding. Recent studies established the presence of prolonged P wave duration and P dispersion as markers of increased risk of AF in hyperthyroid subjects [14,16,29]. Treatment of hyperthyroidism is frequently associated with reversion to sinus rhythm. A recent study showed that reversion to sinus rhythm occurred in 62 percent of 163 patients within 8-10 weeks after they returned to a euthyroid state [30]. Katircibasi et al [29] demonstrated that the prolonged P wave duration and dispersion recovered with PTU treatment at levels measured in healthy control subjects. Our results supports these findings. Therefore, anti-thyroid treatment may have preventive effects in the development of AF in patients with hyperthyroidism.

Impaired left ventricular relaxation has been reported to effect PWD [31]. It has been reported that hyperthyroidism has profound effects on cardiac diastolic function that are at least in part reversible after restoration of euthyroidism [8,32-35]. In the present study, diastolic function parameters of DT and IVRT were increased in hyperthyroid state. In addition, diastolic function was normalized in 4 of 5 patients after achievement in euthyroid state. There were significant correlations between diastolic function and Pmax and PWD. Therefore, improvement in PWD in our study may be partially explained by improvement in diastolic function.

Limitations

Small number of study patients and short-term follow-up are the major limitations. Another important limitation of our study is manual calculation of P-wave parameters using magnifying lens instead of computer-assisted P-wave calculations. We do not have automated measurement facilities for PWD. However, thermal, digital, and signal-averaging ECG systems have been used to evaluate PWD which was measured manually either on paper or on a high-resolution computer screen. Although, several studies have demonstrated a low error of the measurement of P wave dispersion on paper printed ECGs [28,7] others suggested that manual PWD measurement on paper printed ECGs obtained at a standard signal size and paper speed may have a questionable accuracy and reproducibility [37].

Conclusions

Hyperthyroidism is associated with prolonged P wave duration and dispersion. Achievement of euthyroid state with PTU treatment results in shortening of P wave variables. Diastolic function may have a partial effect for the increased Pmax and PWD. However, there is need for larger prospective studies to elucidate the role of P wave disturbances in prediction and early treatment of AF in hyperthyroid patients.

References

1. Kahaly GJ, Dillmann WH. Thyroid hormone action in the heart. *Endocr Rev* 2005; 26: 704–28.
2. Klein I, Ojamaa K. Thyrotoxicosis and the heart. *Endocrinol Metab Clin North Am* 1998; 27: 51–62.
3. Forfar JC, Miller HC, Toft AD. Occult thyrotoxicosis: a reversible cause of idiopathic atrial fibrillation. *Am J Cardiol* 1979; 44: 9–12.
4. Gilligan DM, Ellenbogen KA, Epstein AE. The management of atrial fibrillation. *Am J Med* 1996; 101: 413–21.
5. Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. *N Engl J Med* 1994; 331: 1249–52.
6. Dilaveris PE, Gialafos EJ, Sideris SK, et al. Simple electrocardiographic markers for the prediction of paroxysmal idiopathic atrial fibrillation. *Am Heart J* 1998; 135: 733–8.
7. Aytemir K, Ozer N, Atalar E, et al. P-wave dispersion on 12-lead electrocardiogram in patients with paroxysmal atrial fibrillation. *Pacing Clin Electrophysiol* 2000; 23: 1109–12.
8. Steinberg JS, Zelenkofske S, Wong SC, et al. Value of P wave signal-averaged ECG for predicting atrial fibrillation after cardiac surgery. *Circulation* 1993; 88: 2618–22.
9. Dilaveris PE, Gialafos EJ, Andrikopoulos GK, et al. Clinical and electrocardiographic predictors of recurrent atrial fibrillation. *Pacing Clin Electrophysiol* 2000; 23: 352–358.
10. Klein I. Thyroid hormone and the cardiovascular system. *Am J Med* 1990; 88:631–7.
11. Forfar JC, Muir AL, Sawers SA, et al. Abnormal left ventricular function in hyperthyroidism: evidence for a possible reversible cardiomyopathy. *N Engl J Med* 1982; 307: 1165–70.
12. Polikar R, Burger AG, Scherrer U, et al. The thyroid and the heart. *Circulation* 1993; 87: 1435–41
13. Ching GW, Franklyn JA, Stallard TJ, et al. Cardiac hypertrophy as a result of long-term thyroxine therapy and thyrotoxicosis. *Heart* 1996; 75: 363–8.
14. Fazio S, Palmieri EA, Lombardi G, et al. Effects of thyroid hormone on the cardiovascular system. *Recent Prog Horm Res* 2004; 59: 31–50.
15. Biondi B, Palmieri EA, Lombardi G, et al. Effects of subclinical thyroid dysfunction on the

heart. *Ann Intern Med* 2002; 137: 904–14.

16. Biondi B, Palmieri EA, Lombardi G, et al. Subclinical hypothyroidism and cardiac function. *Thyroid* 2002; 12: 505–10.

17. Biondi B, Palmieri EA, Fazio S, et al. Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients. *J Clin Endocrinol Metab* 2000; 85: 4701–05.

18. Lang RM, Bierig M, Devereux RB, et al; Chamber Quantification Writing Group; American Society of Echocardiography's Guidelines and Standards Committee; European Association of Echocardiography. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. *J Am Soc Echocardiography* 2005; 18: 1440–63.

19. Nagueh SF, Middleton KJ, Kopelen HA, et al. Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. *J Am Coll Cardiol* 1997; 30: 1527–33.

20. Buxton AE, Waxman HL, Marchlinski FE, et al. Atrial conduction: effects of extrastimuli with and without atrial dysrhythmias. *Am J Cardiol* 1984; 54: 755–61.

21. Roithinger FX, Karch MR, Steiner PR. The spatial dispersion of atrial refractoriness and atrial fibrillation vulnerability. *J Interv Card Electrophysiol* 1999; 3: 311–9.

22. Michelucci A, Bagliani G, Colella A, et al. P wave assessment: Statement of the art update. *Card Electrophys Rev* 2002; 6: 215–20.

23. Sun ZQ, Ojamaa K, Coetzee WA. Effects of thyroid hormone on action potential and repolarizing currents in rat ventricular myocytes. *Am J Physiol* 2000; 278: 302–7.

24. Johnson PN, Freedberg AS, Marshall JM. Action of thyroid hormone on the transmembrane potentials from sinoatrial node cells and atrial muscle cells in isolated atria of rabbits. *Cardiology* 1973; 58: 273–89.

25. Han J, Leem C, So I, et al. Effects of thyroid hormone on the calcium current and isoprenaline-induced background current in rabbit ventricular myocytes. *J Mol Cell Cardiol* 1994; 26: 925–35.

26. Aras D, Maden O, Ozdemir O, et al. Simple electrocardiographic markers for the prediction of paroxysmal atrial fibrillation in hyperthyroidism. *Int J Cardiol* 2005; 99: 59–64.

27. Cacciatori V, Bellavere F, Pezzarossa A, et al. Power spectral analysis of heart rate in hyperthyroidism. *J Clin Endocrinol Metab* 1996; 81: 2828–35.

28. Tukek T, Akkaya V, Demirel S, et al. Effect of Valsalva maneuver on surface electrocardiographic P-wave dispersion in paroxysmal atrial fibrillation. *Am J Cardiol* 2000; 85: 896–9.

29. Katircibasi MT, Deniz F, Pamukcu B, et al. Effects of short-term propylthiouracil treatment on p wave duration and p wave dispersion in patients with overt hyperthyroidism. *Exp Clin Endocrinol Diabetes*. 2007; 115: 376-9.
30. Nakazawa HK, Sakurai K, Hamada N, et al. Management of atrial fibrillation in the post-thyrototoxic state. *Am J Med* 1982; 72: 903–6.
31. Gunduz H, Binak E, Arinc Hat et al. The Relationship between P wave dispersion and diastolic dysfunction. *Tex Heart Inst J*. 2005; 32: 163-7.
32. Smit JW, Eustatia-Rutten CF, Corssmit EP, et al. Reversible diastolic dysfunction after long-term exogenous subclinical hyperthyroidism: a randomized, placebo-controlled study. *J Clin Endocrinol Metab*. 2005; 90: 6041-7.
33. Fazio S, Biondi B, Carella C, Sabatini et al. Diastolic dysfunction in patients on thyroid-stimulating hormone suppressive therapy with levothyroxine: beneficial effect of blockade. *J Clin Endocrinol Metab* 1995; 80: 2222–6.
34. Biondi B, Fazio S, Cuocolo A, et al. Impaired cardiac reserve and exercise capacity in patients receiving long-term thyrotropin suppressive therapy with levothyroxine. *J Clin Endocrinol Metab* 1996; 81: 4224–8.
35. Mercurio G, Panzuto MG, Bina A, et al. Cardiac function, physical exercise capacity, and quality of life during long-term thyrotropin-suppressive therapy with levothyroxine: effect of individual dose tailoring. *J Clin Endocrinol Metab* 2000; 85: 159–64.
36. Dilaveris PE, Gialafos JE. P-wave duration and dispersion analysis: methodological considerations. *Circulation* 2001; 103: E111-1.